Health and Healthcare

Why This Seizure Treatment Could Be the Next Big Thing

courtesy of the U.S. Food and Drug Administration

Aquestive Therapeutics Inc. (NASDAQ: AQST) shares jumped early on Monday after the firm announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its therapeutic candidate Libervant (diazepam) buccal film.

Libervant is a buccally, or inside of the cheek, administered soluble film formulation of diazepam, a benzodiazepine intended for rapid treatment of acute uncontrolled seizures to control bouts of increased seizure activity.

Aquestive is developing Libervant as an alternative to Diastat (diazepam rectal gel), the current standard of care rescue therapy for patients with refractory epilepsy, which as a rectal gel, is invasive, inconvenient and difficult to administer.

As a result, a large portion of the patient population does not receive adequate treatment or forgoes treatment altogether. Ultimately, it’s expected that Libervant will enable a larger share of these patients to receive more appropriate treatment by providing consistent therapeutic dosing in a noninvasive and innovative treatment form for epileptic seizures.

Keith J. Kendall, CEO of Aquestive Therapeutics, commented:

We are very pleased to have completed our NDA filing for Libervant as we had committed.  We look forward to sharing the results from the single dose crossover study at the upcoming American Epilepsy Society 2019 Annual Meeting. We believe these results confirm our dosing algorithm and satisfy the final clinical requirement requested by the FDA. We believe that Libervant has the potential to be the first oral therapy approved by the FDA for the management of seizure clusters in the population of 1.2 million refractory epilepsy patients and the first diazepam based treatment usable by and delivering a consistent predictable dose to virtually all patients to whom it will be prescribed.

Shares of Aquestive Therapeutics traded up about 8% to $8.42 early Monday, in a 52-week range of $2.95 to $9.32. The consensus price target is $18.50.


Get Ready To Retire (Sponsored)

Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.

Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.

Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future

Get started right here.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.